tailieunhanh - Temporal and geographic variation in the systemic treatment of advanced prostate cancer

Several systemic treatments have been shown to increase survival for patients with metastatic castration-resistant prostate cancer. This study sought to characterize variation in use of the six “focus drugs” (docetaxel, abiraterone, enzalutamide, sipuleucel-T, radium-223, and cabazitaxel) that have been approved by the Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer during the years 2010–2015. | Temporal and geographic variation in the systemic treatment of advanced prostate cancer

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN